Abstract
Synthetic cannabinoid receptor agonists (SCRAs) are the largest and most structurally diverse class of new psychoactive substances (NPS). Although the earliest SCRA NPS were simply repurposed from historical academic manuscripts or pharmaceutical patents describing cannabinoid ligands, recent examples bear hallmarks of rational design. SCRA NPS manufacturers have applied traditional medicinal chemistry strategies (such as molecular hybridization, bioisosteric replacement, and scaffold hopping) to existing cannabinoid templates in order to generate new molecules that circumvent structure-based legislation. Most SCRAs potently activate cannabinoid type 1 and type 2 receptors (CB1 and CB2, respectively), with the former contributing to the psychoactivity of these substances. SCRAs are generally more toxic than the Δ9-tetrahydrocannabinol (Δ9-THC) found in cannabis, and this may be due to ligand bias, metabolism, or off-target activity. This chapter will chart the evolution of recently identified SCRA NPS chemotypes, as well as their putative manufacturing by-products and thermolytic degradants, and describe structure-activity relationships within each class.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- Δ9-THC:
-
(6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol (Δ9-tetrahydrocannabinol)
- 3-CAF:
-
Naphthalen-2-yl 1-(2-fluorophenyl)-1H-indazole-3-carboxylate
- 4-HTMPIPO:
-
4-Hydroxy-3,3,4-trimethyl-1-(1-pentyl-1H-indol-3-yl)pentan-1-one
- 5Cl-NNEI:
-
1-(5-Chloropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide
- 5Cl-UR-144:
-
[1-(5-Chloropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone
- 5F-AB-FUPPYCA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
- 5F-AB-PICA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-fluoropentyl)-1H-indole-3-carboxamide
- 5F-AB-PINACA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
- 5F-ADB-PICA:
-
N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(5-fluoropentyl)-1H-indole-3-carboxamide
- 5F-ADB-PINACA:
-
N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
- 5F-AKB-57:
-
Adamantan-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate
- 5F-AKB-48-7N:
-
N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide
- 5F-AMB-PICA:
-
Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3-methylbutanoate
- 5F-AMB-PINACA:
-
Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3-methylbutanoate
- 5F-AMPPPCA:
-
N-(Adamantan-1-yl)-1-(5-fluoropentyl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxamide
- 5F-APICA:
-
N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide
- 5F-APINACA:
-
N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
- 5F-CUMYL-PICA:
-
1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide
- 5F-CUMYL-PINACA:
-
1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
- 5F-MDMB-PICA:
-
Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate
- 5F-MDMB-PINACA:
-
Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate
- 5F-MN-18:
-
1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indazole-3-carboxamide
- 5F-NNEI:
-
1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide
- 5F-NPB-22-7N:
-
Quinolin-8-yl 1-(5-fluoropentyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate
- 5F-PB-22:
-
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate
- 5F-PCN:
-
1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridine-3-carboxamide
- 5F-SBD-005:
-
Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate
- A-836339:
-
N-(3-(2-methoxyethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethylcyclopropane-1-carboxamide
- AB-001:
-
(Adamantan-1-yl)(1-pentyl-1H-indol-3-yl)methanone
- AB-005-azepane:
-
(1-(1-Methylazepan-3-yl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
- AB-CHFUPYCA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide
- AB-CHMINACA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
- AB-CHMINACA-2H-indazole:
-
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-2-(cyclohexylmethyl)-2H-indazole-3-carboxamide
- AB-FUBICA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxamide
- AB-FUBINACA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
- AB-PICA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indole-3-carboxamide
- AB-PINACA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-carboxamide
- ADB-CHMINACA:
-
N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
- ADB-FUBICA:
-
N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxamide
- ADB-FUBINACA:
-
N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
- ADB-PICA:
-
N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-pentyl-1H-indole-3-carboxamide
- ADSB-FUB-187:
-
7-Chloro-N-[(2S)-1-({2-[(cyclopropanesulfonyl)amino]ethyl}amino)-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
- APP-FUBINACA:
-
N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
- AKB-48:
-
N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide
- AM-2201:
-
[1-(5-Fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone
- AMB-CHMICA:
-
Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino}-3-methylbutanoate
- AMB-CHMINACA:
-
Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino}-3-methylbutanoate
- AMB-FUBICA:
-
Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indole-3-carbonyl}amino)-3-methylbutanoate
- AMB-FUBINACA:
-
Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate
- AMB-PICA:
-
Methyl (2S)-2-[(1-pentyl-1H-indole-3-carbonyl)amino]-3-methylbutanoate
- AMB-PINACA:
-
Methyl (2S)-2-[(1-pentyl-1H-indazole-3-carbonyl)amino]-3-methylbutanoate
- AMPPPCA:
-
N-(Adamantan-1-yl)-4-methyl-1-pentyl-5-phenyl-1H-pyrazole-3-carboxamide
- APICA:
-
N-(Adamantan-1-yl)-1-pentyl-1H-indole-3-carboxamide
- APINAC:
-
Adamantan-1-yl 1-pentyl-1H-indazole-3-carboxylate
- APINACA:
-
N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide
- APINACA-2H-indazole:
-
N-(Adamantan-1-yl)-2-pentyl-2H-indazole-3-carboxamide
- BB-22:
-
Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate
- BIM-018:
-
(Naphthalen-1-yl)(1-pentyl-1H-benzimidazol-2-yl)methanone
- BiPICANA:
-
N-(Naphthalen-1-yl)-1-pentyl-N-(1-pentyl-1H-indole-3-carbonyl)-1H-indole-3-carboxamide
- BzODZ-EPyr:
-
3-Benzyl-5-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-3-yl)-1,2,4-oxadiazole
- CBL-018:
-
Naphthalen-1-yl 1-pentyl-1H-indole-3-carboxylate
- CBL-2201:
-
Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate
- CP 47,497-C8:
-
2-[(1S,3R)-3-Hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol
- CUMYL-4CN-B7AICA:
-
1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide
- CUMYL-5F-P7AICA:
-
1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide
- CUMYL-BICA:
-
1-Butyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide
- CUMYL-BINACA:
-
1-Butyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
- CUMYL-CHMICA:
-
1-(Cyclohexylmethyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide
- CUMYL-CHMINACA:
-
1-(Cyclohexylmethyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
- CUMYL-FUBICA:
-
1-(4-Fluorobenzyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide
- CUMYL-FUBINACA:
-
1-(4-Fluorobenzyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
- CUMYL-PEGACLONE:
-
5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one
- CUMYL-PICA:
-
1-Pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide
- CUMYL-PINACA:
-
1-Pentyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
- DP-UR-144:
-
(1H-Indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
- EG-018:
-
(Naphthalen-1-yl)(9-pentyl-9H-carbazol-3-yl)methanone
- EG-2201:
-
[9-(5-Fluoropentyl)-9H-carbazol-3-yl](naphthalen-1-yl)methanone
- FAB-144:
-
[1-(5-Fluoropentyl)-1H-indazol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone
- FDU-NNEI:
-
1-[(4-Fluorophenyl)methyl]-N-(naphthalen-1-yl)-1H-indole-3-carboxamide
- FDU-PB-22:
-
Naphthalen-1-yl 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylate
- FUB-144:
-
{1-[(4-Fluorophenyl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone
- FUB-AKB-48:
-
N-(Adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
- FUB-PB-22:
-
Quinolin-8-yl 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylate
- FUBIMINA:
-
[1-(5-Fluoropentyl)-1H-benzimidazol-2-yl](naphthalen-1-yl)methanone
- JWH-018:
-
(Naphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone
- M-5FPIC:
-
Methyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate
- MCBH-1:
-
1-(Cyclohexylmethyl)-2-(4-ethoxybenzyl)-N,N-diethyl-1H-benzo[d]imidazole-5-carboxamide
- M-CHMIC:
-
Methyl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate
- MDMB-CHMCZCA:
-
Methyl (2S)-2-{[9-(cyclohexylmethyl)-9H-carbazole-3-carbonyl]amino}-3,3-dimethylbutanoate
- MDMB-CHMICA:
-
Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate
- MDMB-CHMINACA:
-
Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate
- MDMB-FUBICA:
-
Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indole-3-carbonyl}amino)-3,3-dimethylbutanoate
- MDMB-FUBINACA:
-
Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3,3-dimethylbutanoate
- MDMB-PICA:
-
Methyl (2S)-3,3-dimethyl-2-[(1-pentyl-1H-indole-3-carbonyl)amino]butanoate
- MDMB-PINACA:
-
Methyl (2S)-3,3-dimethyl-2-[(1-pentyl-1H-indazole-3-carbonyl)amino]butanoate
- MEPIRAPIM:
-
(4-Methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone
- MN-001:
-
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
- MN-18:
-
N-(Naphthalen-1-yl)-1-pentyl-1H-indazole-3-carboxamide
- MN-25:
-
7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-indole-3-carboxamide
- NMP-7:
-
(9-Pentyl-9H-carbazol-3-yl)(piperidin-1-yl)methanone
- NNEI:
-
N-(Naphthalen-1-yl)-1-pentyl-1H-indazole-3-carboxamide
- NNEI-2H-indazole:
-
N-(Naphthalen-1-yl)-2-pentyl-2H-indazole-3-carboxamide
- NNL-3:
-
1-{[1-(5-Fluoropentyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]oxy}-1H-benzotriazole
- N-Phenyl-SDB-006:
-
1-Pentyl-N-phenyl-1H-indole-3-carboxamide
- Org-28611:
-
(S)-(1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl)(3,4-dimethylpiperazin-1-yl)methanone
- PB-22:
-
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate
- PTI-1:
-
N-Ethyl-N-{[2-(1-pentyl-1H-indol-3-yl)-1,3-thiazol-4-yl]methyl}ethanamine
- PTI-2:
-
N-(2-Methoxyethyl)-N-{[2-(1-pentyl-1H-indol-3-yl)-1,3-thiazol-4-yl]methyl}propan-2-amine
- QMPSB:
-
Quinolin-8-yl 4-methyl-3-(piperidine-1-sulfonyl)benzoate
- RCS-4-N-Me:
-
(4-Methoxyphenyl)(1-methyl-1H-indol-3-yl)methanone
- SBD-005:
-
Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate
- SBD-006:
-
N-Benzyl-1-pentyl-1H-indole-3-carboxamide
- THJ-018:
-
(Naphthalen-1-yl)(1-pentyl-1H-indazol-3-yl)methanone
- THJ-2201:
-
[1-(5-Fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone
- TMCP-020:
-
(1-Heptyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
- UR-144:
-
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
- XLR-11:
-
[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone
References
Adam J (2008) Indole derivatives. World Patent 2,008,101,995
Adam JM, Cairns J, Caulfield W, Cowley P, Cumming I, Easson M, Edwards D, Ferguson M, Goodwin R, Jeremiah F, Kiyoi T, Mistry A, Moir E, Morphy R, Tierney J, York M, Baker J, Cottney JE, Houghton AK, Westwood PJ, Walker G (2010) Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists. Med Chem Commun 1:54
Adamowicz P (2016) Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int 261:e5–e10
Adamowicz P, Zuba D, Sekula K (2013) Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci Int 233:320–327
Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585–1614
Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R (2017) “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med 376:235–242
Adam-Worrall J, Morrison AJ, Wishart G, Kiyoi T, Mcarthur DR (2005) Preparation of (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid CB1 receptor. World Patent 2,005,089,754
Andernach L, Pusch S, Weber C, Schollmeyer D, Munster-Muller S, Putz M, Opatz T (2016) Absolute configuration of the synthetic cannabinoid MDMB-CHMICA with its chemical characteristics in illegal products. Forensic Toxicol 34:344–352
Angerer V, Jacobi S, Franz F, Auwarter V, Pietsch J (2017) Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA. Forensic Sci Int 281:e9–e15
Angerer V, Mogler L, Steitz JP, Bisel P, Hess C, Schoeder CT, Muller CE, Huppertz LM, Westphal F, Schaper J, Auwarter V (2018) Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE. Drug Test Anal 10:597–603
Babi MA, Robinson CP, Maciel CB (2017) A spicy status: synthetic cannabinoid (spice) use and new-onset refractory status epilepticus-A case report and review of the literature. SAGE Open Med Case Rep 5:2050313X17745206
Backberg M, Tworek L, Beck O, Helander A (2017) Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA project. J Med Toxicol 13:52–60
Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, Brooker L, Goebel C, Hibbs DE, Glass M, Connor M, Mcgregor IS, Kassiou M (2013) The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem Neurosci 4:1081–1092
Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, Mcgregor IS, Kassiou M (2015a) Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci 6:1546–1559
Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, Mcgregor IS, Kassiou M (2015b) Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci 6:1445–1458
Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JB, Glass M, Mcgregor IS, Connor M, Kassiou M (2016) Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci 7:1241–1254
Behonick G, Shanks KG, Firchau DJ, Mathur G, Lynch CF, Nashelsky M, Jaskierny DJ, Meroueh C (2014) Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol 38:559–562
Bell S, Nida C (2015) Pyrolysis of drugs of abuse: a comprehensive review. Drug Test Anal 7:445–456
Blaazer AR, Lange JH, Van Der Neut MA, Mulder A, Den Boon FS, Werkman TR, Kruse CG, Wadman WJ (2011) Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity. Eur J Med Chem 46:5086–5098
Blakey K, Boyd S, Atkinson S, Wolf J, Slottje PM, Goodchild K, Mcgowan J (2016) Identification of the novel synthetic cannabimimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) and other designer drugs in herbal incense. Forensic Sci Int 260:40–53
Böhm H-J, Flohr A, Stahl M (2004) Scaffold hopping. Drug Discov Today Technol 1:217–224
Bovens M, Bissig C, Staeheli SN, Poetzsch M, Pfeiffer B, Kraemer T (2017) Structural characterization of the new synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA. Forensic Sci Int 281:98–105
Bowden MJ, Williamson JPB (2014) Preparation of cannabinoid indole and indazole compounds for treating pain and nausea, stimulating appetite, and inducing a positive mood change. World Patent 2,014,167,530
Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6:e21917
Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK (2009a) Indazole derivatives as CB1 receptor modulators and their preparation and use in the treatment of CB1-mediated diseases. World Patent 2,009,106,982
Buchler IP, Hayes MJ, Hegde SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK (2009b) Indazole derivatives as CB1 receptor modulators and their preparation and use in treatment of diseases. World Patent 2,009,106,980
Buser GL, Gerona RR, Horowitz BZ, Vian KP, Troxell ML, Hendrickson RG, Houghton DC, Rozansky D, Su SW, Leman RF (2014) Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol 52:664–673
Canazza I, Ossato A, Trapella C, Fantinati A, De Luca MA, Margiani G, Vincenzi F, Rimondo C, Di Rosa F, Gregori A, Varani K, Borea PA, Serpelloni G, Marti M (2016) Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology 233:3685–3709
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41
Centers for Disease Control and Prevention (2013) Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep 62:93–98
Chen BC, Chen P, Hynes J, Kiener P, Leftheris K, Longphre M, Norris DJ, Pandit CR, Spergel S, Tokarski J (2002) Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases. World Patent 2,001,058,869
Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40:2174–2184
Choi H, Heo S, Kim E, Hwang BY, Lee C, Lee J (2013) Identification of (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone and its 5-pentyl fluorinated analog in herbal incense seized for drug trafficking. Forensic Toxicol 31:86–92
Chung H, Choi H, Heo S, Kim E, Lee J (2014) Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013. Forensic Toxicol 32:82–88
Cohen K, Weinstein A (2018) The effects of cannabinoids on executive functions: evidence from cannabis and synthetic cannabinoids – a systematic review. Brain Sci 8:40
D’ambra TE, Eissenstat MA, Abt J, Ackerman JH, Bacon ER, Bell MR, Carabateas PM, Josef KA, Kumar V, Weaver JD, Arnold R, Casiano FM, Chippari SM, Haycock DA, Kuster JE, Luttinger DA, Stevenson JI, Ward SJ, Hill WA, Khanolkar A, Makriyannis A (1996) C-attached aminoalkylindoles: potent cannabinoid mimetics. Bioorg Med Chem Lett 6:17–22
Diao X, Scheidweiler KB, Wohlfarth A, Pang S, Kronstrand R, Huestis MA (2016a) In vitro and in vivo human metabolism of synthetic cannabinoids FDU-PB-22 and FUB-PB-22. AAPS J 18:455–464
Diao X, Scheidweiler KB, Wohlfarth A, Zhu M, Pang S, Huestis MA (2016b) Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. Forensic Toxicol 34:256–267
Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA (2016c) High-resolution mass spectrometry for characterizing the metabolism of synthetic cannabinoid THJ-018 and its 5-fluoro analog THJ-2201 after incubation in human hepatocytes. Clin Chem 62:157–169
Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, Huestis MA (2017) In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicol 35:20–32
Dobaja M, Grenc D, Kozelj G, Brvar M (2017) Occupational transdermal poisoning with synthetic cannabinoid cumyl-PINACA. Clin Toxicol 55:193–195
Doi T, Asada A, Takeda A, Tagami T, Katagi M, Kamata H, Sawabe Y (2016) Enantioseparation of the carboxamide-type synthetic cannabinoids N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide and methyl [1-(5-fluoropentyl)-1H-indazole-3-carbonyl]-valinate in illicit herbal products. J Chromatogr A 1473:83–89
Doi T, Tagami T, Takeda A, Asada A, Sawabe Y (2018) Evaluation of carboxamide-type synthetic cannabinoids as CB1/CB2 receptor agonists: difference between the enantiomers. Forensic Toxicol 36:51–60
European Monitoring Centre for Drugs and Drug Addiction (2014) EMCDDA–Europol 2013 annual report on the implementation of Council Decision 2005/387/JHA, implementation reports. Publications Office of the European Union, Luxembourg
European Monitoring Centre for Drugs and Drug Addiction (2016) EMCDDA–Europol 2015 annual report on the implementation of Council Decision 2005/387/JHA, implementation reports. Publications Office of the European Union, Luxembourg
European Monitoring Centre for Drugs and Drug Addiction (2017) EMCDDA–Europol 2016 annual report on the implementation of Council Decision 2005/387/JHA, implementation reports. Publications Office of the European Union, Luxembourg
Fantegrossi WE, Wilson CD, Berquist MD (2018) Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev 50:65–73
Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Miller LN, Li L, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD (2008) Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity. J Med Chem 51:1904–1912
Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD (2010) Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem 53:295–315
Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, Mcgregor IS, Wiley JL, Thomas BF (2018) Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA. J Pharmacol Exp Ther. https://doi.org/10.1124/jpet.117.246983
Gatch MB, Forster MJ (2014) Delta9-tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice. Behav Pharmacol 25:750–757
Gatch MB, Forster MJ (2015) Delta9-tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market. Behav Pharmacol 26:460–468
Gatch MB, Forster MJ (2016) Delta(9)-tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats. Psychopharmacology 233:1901–1910
Gatch MB, Forster MJ (2018) Delta(9)-tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats. Psychopharmacology 235:673–680
Girreser U, Rosner P, Vasilev A (2016) Structure elucidation of the designer drug N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-py razole-5-carboxamide and the relevance of predicted (13) C NMR shifts – a case study. Drug Test Anal 8:668–675
Grigoryev A, Kavanagh P, Melnik A, Savchuk S, Simonov A (2013) Gas and liquid chromatography-mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J Anal Toxicol 37:265–276
Gugelmann H, Gerona R, Li C, Tsutaoka B, Olson KR, Lung D (2014) ‘Crazy Monkey’ poisons man and dog: human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol 52:635–638
Hartung B, Kauferstein S, Ritz-Timme S, Daldrup T (2014) Sudden unexpected death under acute influence of cannabis. Forensic Sci Int 237:e11–e13
Hess C, Schoeder CT, Pillaiyar T, Madea B, Muller CE (2016) Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicol 34:329–343
Hwang J, Hwang J, Ganganna B, Song I, Heo MY, Ahn S-H, Lee J (2017) Metabolic and pharmacokinetic characterization of a new synthetic cannabinoid APINAC in rats. Forensic Toxicol 36:88–101
Hynes J Jr, Leftheris K, Wu H, Pandit C, Chen P, Norris DJ, Chen B-C, Zhao R, Kiener PA, Chen X, Turk LA, Patil-Koota V, Gillooly KM, Shuster DJ, Mcintyre KW (2002) C-3 amido-indole cannabinoid receptor modulators. Bioorg Med Chem Lett 12:2399–2402
Ichikawa Y, Nakajima JI, Takahashi M, Uemura N, Yoshida M, Suzuki A, Suzuki J, Nakae D, Moriyasu T, Hosaka M (2016) Identification of (1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (DP-UR-144) in a herbal drug product that was commercially available in the Tokyo metropolitan area. Forensic Toxicol 35:146–152
Jia W, Meng X, Qian Z, Hua Z, Li T, Liu C (2017) Identification of three cannabimimetic indazole and pyrazole derivatives, APINACA 2H-indazole analogue, AMPPPCA, and 5F-AMPPPCA. Drug Test Anal 9:248–255
Jung ME, Piizzi G (2005) gem-disubstituent effect: theoretical basis and synthetic applications. Chem Rev 105:1735–1766
Kaizaki-Mitsumoto A, Hataoka K, Funada M, Odanaka Y, Kumamoto H, Numazawa S (2017) Pyrolysis of UR-144, a synthetic cannabinoid, augments an affinity to human CB1 receptor and cannabimimetic effects in mice. J Toxicol Sci 42:335–341
Kavanagh P, Grigoryev A, Savchuk S, Mikhura I, Formanovsky A (2013) UR-144 in products sold via the Internet: identification of related compounds and characterization of pyrolysis products. Drug Test Anal 5:683–692
Kevin RC, Wood KE, Stuart J, Mitchell AJ, Moir M, Banister SD, Kassiou M, Mcgregor IS (2017) Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. J Psychopharmacol 31:757–769
Kneisel S, Bisel P, Brecht V, Broecker S, Müller M, Auwärter V (2012) Identification of the cannabimimetic AM-1220 and its azepane isomer (N-methylazepan-3-yl)-3-(1-naphthoyl)indole in a research chemical and several herbal mixtures. Forensic Toxicol 30:126–134
Kondrasenko AA, Goncharov EV, Dugaev KP, Rubaylo AI (2015) CBL-2201. Report on a new designer drug: napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate. Forensic Sci Int 257:209–213
Lambeng N, Lebon F, Christophe B, Burton M, De Ryck M, Quéré L (2007) Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies. Bioorg Med Chem Lett 17:272–277
Lamy FR, Daniulaityte R, Nahhas RW, Barratt MJ, Smith AG, Sheth A, Martins SS, Boyer EW, Carlson RG (2017) Increases in synthetic cannabinoids-related harms: results from a longitudinal web-based content analysis. Int J Drug Policy 44:121–129
Lange JH, Attali A, van der Neut MA, Wals HC, Mulder A, Zilaout H, Duursma A, van Aken HH, van Vliet BJ (2010) Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists. Bioorg Med Chem Lett 20:4992–4998
Langer N, Lindigkeit R, Schiebel HM, Ernst L, Beuerle T (2014) Identification and quantification of synthetic cannabinoids in ‘spice-like’ herbal mixtures: a snapshot of the German situation in the autumn of 2012. Drug Test Anal 6:59–71
Langer N, Lindigkeit R, Schiebel HM, Papke U, Ernst L, Beuerle T (2016) Identification and quantification of synthetic cannabinoids in “spice-like” herbal mixtures: update of the German situation for the spring of 2016. Forensic Sci Int 269:31–41
Lee JH, Park HN, Leem T-S, Jeon J-H, Cho S, Lee J, Baek SY (2016) Identification of new synthetic cannabinoid analogue APINAC (adamantan-1-yl 1-pentyl-1H-indazole-3-carboxylate) with other synthetic cannabinoid MDMB(N)-Bz-F in illegal products. Forensic Toxicol 35:45–55
Liu C, Jia W, Hua Z, Qian Z (2017) Identification and analytical characterization of six synthetic cannabinoids NNL-3, 5F-NPB-22-7N, 5F-AKB-48-7N, 5F-EDMB-PINACA, EMB-FUBINACA, and EG-018. Drug Test Anal 9:1251–1261
Longworth M, Banister SD, Mack JB, Glass M, Connor M, Kassiou M (2016) The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicol 34:286–303
Longworth M, Banister SD, Boyd R, Kevin RC, Connor M, Mcgregor IS, Kassiou M (2017a) Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues. ACS Chem Neurosci 8:2159–2167
Longworth M, Connor M, Banister SD, Kassiou M (2017b) Synthesis and pharmacological profiling of the metabolites of synthetic cannabinoid drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA. ACS Chem Neurosci 8:1673–1680
Louis A, Peterson BL, Couper FJ (2014) XLR-11 and UR-144 in Washington state and state of Alaska driving cases. J Anal Toxicol 38:563–568
Maeda H, Nagashima E, Hayashi YK, Kikura-Hanajiri R, Yoshida K-I (2018) MDMB-CHMICA induces thrashing behavior, bradycardia, and slow pressor response in a CB1- and CB2-receptor-dependent manner in conscious rats. Forensic Toxicol. https://doi.org/10.1007/s11419-018-0405-1
Makriyannis A, Liu Q (2003) Heteroindanes: a new class of potent cannabimimetic ligands. World Patent 2,003,035,005
Mclaughlin G, Morris N, Kavanagh PV, Power JD, Twamley B, O’brien J, Talbot B, Dowling G, Brandt SD (2016) The synthesis and characterization of the ‘research chemical’ N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-p yrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer. Drug Test Anal 8:920–929
Moloney GP, Robertson AD (2002) 3-Oxadiazol-5-yl-1-aminoalkyl-1H-indole derivatives. World Patent 2,002,036,590
Moloney GP, Angus JA, Robertson AD, Stoermer MJ, Robinson M, Wright CE, Mcrae K, Christopoulos A (2008) Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. Eur J Med Chem 43:513–539
Monte AA, Bronstein AC, Cao DJ, Heard KJ, Hoppe JA, Hoyte CO, Iwanicki JL, Lavonas EJ (2014) An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med 370:389–390
Morrison AJ, Adam JM, Baker JA, Campbell RA, Clark JK, Cottney JE, Deehan M, Easson A-M, Fields R, Francis S, Jeremiah F, Keddie N, Kiyoi T, Mcarthur DR, Meyer K, Ratcliffe PD, Schulz J, Wishart G, Yoshiizumi K (2011) Design, synthesis, and structure–activity relationships of indole-3-heterocycles as agonists of the CB1 receptor. Bioorg Med Chem Lett 21:506–509
Nacca N, Vatti D, Sullivan R, Sud P, Su M, Marraffa J (2013) The synthetic cannabinoid withdrawal syndrome. J Addict Med 7:296–298
Nakajima JI, Takahashi M, Seto T, Kanai C, Suzuki J, Yoshida M, Uemura N, Hamano T (2013) Analysis of azepane isomers of AM-2233 and AM-1220, and detection of an inhibitor of fatty acid amide hydrolase [3′-(aminocarbonyl)(1,1′-biphenyl)-3-yl]-cyclohexylcarbamate (URB597) obtained as designer drugs in the Tokyo area. Forensic Toxicol 31:76–85
Nakajima JI, Takahashi M, Uemura N, Seto T, Fukaya H, Suzuki J, Yoshida M, Kusano M, Nakayama H, Zaitsu K, Ishii A, Moriyasu T, Nakae D (2014) Identification of N,N-bis(1-pentylindol-3-yl-carboxy)naphthylamine (BiPICANA) found in an herbal blend product in the Tokyo metropolitan area and its cannabimimetic effects evaluated by in vitro [35S]GTPγS binding assays. Forensic Toxicol 33:84–92
Pagé D, Balaux E, Boisvert L, Liu Z, Milburn C, Tremblay M, Wei Z, Woo S, Luo X, Cheng Y-X, Yang H, Srivastava S, Zhou F, Brown W, Tomaszewski M, Walpole C, Hodzic L, St-Onge S, Godbout C, Salois D, Payza K (2008) Novel benzimidazole derivatives as selective CB2 agonists. Bioorg Med Chem Lett 18:3695–3700
Patani GA, Lavoie EJ (1996) Bioisosterism: a rational approach in drug design. Chem Rev 96:3147–3176
Pertwee RG (2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168:1–51
Petrov RR, Knight L, Chen SR, Wager-Miller J, Mcdaniel SW, Diaz F, Barth F, Pan HL, Mackie K, Cavasotto CN, Diaz P (2013) Mastering tricyclic ring systems for desirable functional cannabinoid activity. Eur J Med Chem 69:881–907
Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL (2013) Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 269:100–108
Ratcliffe P, Adam JM, Baker J, Bursi R, Campbell R, Clark JK, Cottney JE, Deehan M, Easson A-M, Ecker D, Edwards D, Epemolu O, Evans L, Fields R, Francis S, Harradine P, Jeremiah F, Kiyoi T, Mcarthur D, Morrison A, Passier P, Pick J, Schnabel PG, Schulz J, Steinbrede H, Walker G, Westwood P, Wishart G, Haes JUD (2011) Design, synthesis and structure–activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate. Bioorg Med Chem Lett 21:2541–2546
Savchuk S, Appolonova S, Pechnikov A, Rizvanova L, Shestakova K, Tagliaro F (2017) In vivo metabolism of the new synthetic cannabinoid APINAC in rats by GC–MS and LC–QTOF-MS. Forensic Toxicol 35:359–368
Schep LJ, Slaughter RJ, Hudson S, Place R, Watts M (2015) Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol 34:557–560
Schindler CW, Gramling BR, Justinova Z, Thorndike EB, Baumann MH (2017) Synthetic cannabinoids found in “spice” products alter body temperature and cardiovascular parameters in conscious male rats. Drug Alcohol Depend 179:387–394
Schreiber S, Bader M, Lenchinski T, Meningher I, Rubovitch V, Katz Y, Cohen E, Gabet Y, Rotenberg M, Wolf EU, Pick CG (2018) Functional effects of synthetic cannabinoids versus delta(9)-THC in mice on body temperature, nociceptive threshold, anxiety, cognition, locomotor/exploratory parameters and depression. Addict Biol. https://doi.org/10.1111/adb.12606
Shanks KG, Behonick GS, Dahn T, Terrell A (2013) Identification of novel third-generation synthetic cannabinoids in products by ultra-performance liquid chromatography and time-of-flight mass spectrometry. J Anal Toxicol 37:517–525
Shanks KG, Winston D, Heidingsfelder J, Behonick G (2015) Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int 252:e6–e9
Shanks KG, Clark W, Behonick G (2016) Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. J Anal Toxicol 40:236–239
Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Morzherin Y, Shafran Y (2013a) Identification and analytical properties of new synthetic cannabimimetics bearing 2,2,3,3-tetramethylcyclopropanecarbonyl moiety. Forensic Sci Int 226:62–73
Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y (2013b) Analytical characterization of some synthetic cannabinoids, derivatives of indole-3-carboxylic acid. Forensic Sci Int 232:1–10
Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Morzherin Y, Shafran Y (2014) 3-Naphthoylindazoles and 2-naphthoylbenzoimidazoles as novel chemical groups of synthetic cannabinoids: chemical structure elucidation, analytical characteristics and identification of the first representatives in smoke mixtures. Forensic Sci Int 242:72–80
Shevyrin V, Melkozerov V, Eltsov O, Shafran Y, Morzherin Y (2016a) Synthetic cannabinoid 3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole. The first detection in illicit market of new psychoactive substances. Forensic Sci Int 259:95–100
Shevyrin V, Melkozerov V, Endres GW, Shafran Y, Morzherin Y (2016b) On a new cannabinoid classification system: a sight on the illegal market of novel psychoactive substances. Cannabis Cannabinoid Res 1:186–194
Silva JP, Carmo H, Carvalho F (2018) The synthetic cannabinoid XLR-11 induces in vitro nephrotoxicity by impairment of endocannabinoid-mediated regulation of mitochondrial function homeostasis and triggering of apoptosis. Toxicol Lett 287:59–69
Simolka K, Lindigkeit R, Schiebel H-M, Papke U, Ernst L, Beuerle T (2012) Analysis of synthetic cannabinoids in “spice-like” herbal highs: snapshot of the German market in summer 2011. Anal Bioanal Chem 404:157–171
Sobolevsky T, Prasolov I, Rodchenkov G (2012) Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 4:745–753
Springer YP, Gerona R, Scheunemann E, Shafer SL, Lin T, Banister SD, Cooper MP, Castrodale LJ, Levy M, Butler JC, Mclaughlin JB (2016) Increase in adverse reactions associated with use of synthetic cannabinoids – Anchorage, Alaska, 2015-2016. MMWR Morb Mortal Wkly Rep 65:1108–1111
Surmont T, Daníelsson HV, Hughes B, Sedefov R (2017) The “Spice” trade. Int Crim Just Rev: 105756771774534
Tai S, Fantegrossi WE (2017) Pharmacological and toxicologicaleffects of synthetic cannabinoids and their metabolites. In: Baumann MH, Glennon RA, Wiley JL (eds) Neuropharmacology of new psychoactive substances (NPS): the science behind the headlines. Springer, Cham
Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 54:1–13
Talele TT (2018) Natural-products-inspired use of the gem-dimethyl group in medicinal chemistry. J Med Chem 61:2166–2210
Tapp L, Ramsey JG, Wen A, Gerona R (2017) Synthetic cannabinoid and mitragynine exposure of law enforcement agents during the raid of an illegal laboratory – Nevada, 2014. MMWR Morb Mortal Wkly Rep 66:1291–1294
Theunissen EL, Hutten N, Mason NL, Toennes SW, Kuypers KPC, De Sousa Fernandes Perna EB, Ramaekers JG (2018) Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study. Br J Pharmacol 175:18–28
Thomas BF, Lefever TW, Cortes RA, Grabenauer M, Kovach AL, Cox AO, Patel PR, Pollard GT, Marusich JA, Kevin RC, Gamage TF, Wiley JL (2017) Thermolytic degradation of synthetic cannabinoids: chemical exposures and pharmacological consequences. J Pharmacol Exp Ther 361:162–171
Thornton SL, Wood C, Friesen MW, Gerona RR (2013) Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol 51:189–190
Trecki J, Gerona RR, Schwartz MD (2015) Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373:103–107
Tsujikawa K, Yamamuro T, Kuwayama K, Kanamori T, Iwata YT, Inoue H (2013) Thermal degradation of a new synthetic cannabinoid QUPIC during analysis by gas chromatography–mass spectrometry. Forensic Toxicol 32:201–207
Tyndall JA, Gerona R, De Portu G, Trecki J, Elie MC, Lucas J, Slish J, Rand K, Bazydlo L, Holder M, Ryan MF, Myers P, Iovine N, Plourde M, Weeks E, Hanley JR, Endres G, St Germaine D, Dobrowolski PJ, Schwartz M (2015) An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol 53:950–956
Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2012) Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol 30:114–125
Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2013a) URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 227:21–32
Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013b) Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 31:223–240
Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014a) Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide Noopept (GVS-111), with synthetic cannabinoid A-834735, cathinone derivative 4-methoxy-α-PVP, and phenethylamine derivative 4-methylbuphedrine from illegal products. Forensic Toxicol 32:9–18
Uchiyama N, Matsuda S, Kawamura M, Shimokawa Y, Kikura-Hanajiri R, Aritake K, Urade Y, Goda Y (2014b) Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, alpha-PHPP and alpha-POP, with 11 newly distributed designer drugs in illegal products. Forensic Sci Int 243:1–13
Uchiyama N, Shimokawa Y, Kawamura M, Kikura-Hanajiri R, Hakamatsuka T (2014c) Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products. Forensic Toxicol 32:266–281
Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014d) Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol 32:105–115
Uchiyama N, Asakawa K, Kikura-Hanajiri R, Tsutsumi T, Hakamatsuka T (2015a) A new pyrazole-carboxamide type synthetic cannabinoid AB-CHFUPYCA [N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide] identified in illegal products. Forensic Toxicol 33:367–373
Uchiyama N, Shimokawa Y, Kikura-Hanajiri R, Demizu Y, Goda Y, Hakamatsuka T (2015b) A synthetic cannabinoid FDU-NNEI, two 2-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative -OH-EDMA, and a cathinone derivative dimethoxy-alpha-PHP, newly identified in illegal products. Forensic Toxicol 33:244–259
Uemura N, Fukaya H, Kanai C, Yoshida M, Nakajima JI, Takahashi M, Suzuki J, Moriyasu T, Nakae D (2014) Identification of a synthetic cannabinoid A-836339 as a novel compound found in a product. Forensic Toxicol 32:45–50
Usui K, Fujita Y, Kamijo Y, Kokaji T, Funayama M (2018) Identification of 5-Fluoro ADB in human whole blood in four death cases. J Anal Toxicol 42:e21–e25
Van Hout MC, Hearne E (2016) User experiences of development of dependence on the synthetic cannabinoids, 5f-AKB48 and 5F-PB-22, and subsequent withdrawal syndromes. Int J Ment Heal Addict 15:565–579
Vineis P, Pirastu R (1997) Aromatic amines and cancer. Cancer Causes Control 8:346–355
Weber C, Pusch S, Schollmeyer D, Münster-Müller S, Pütz M, Opatz T (2016) Characterization of the synthetic cannabinoid MDMB-CHMCZCA. Beilstein J Org Chem 12:2808–2815
Westphal F, Sonnichsen FD, Knecht S, Auwarter V, Huppertz L (2015) Two thiazolylindoles and a benzimidazole: novel compounds on the designer drug market with potential cannabinoid receptor activity. Forensic Sci Int 249:133–147
Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Moore KN, Thomas BF (2013) Cannabinoids in disguise: delta9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology 75:145–154
Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, Patel PR, Grabenauer M, Moore KN, Thomas BF (2015) AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing delta9-tetrahydrocannabinol-like effects in mice. J Pharmacol Exp Ther 354:328–339
Wiley JL, Lefever TW, Marusich JA, Grabenauer M, Moore KN, Huffman JW, Thomas BF (2016) Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice. Neuropharmacology 110:143–153
Willis PG, Pavlova OA, Chefer SI, Vaupel DB, Mukhin AG, Horti AG (2005) Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. J Med Chem 48:5813–5822
Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA (2014) Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem 406:1763–1780
Wrobleski ST, Chen P, Hynes J, Lin S, Norris DJ, Pandit CR, Spergel S, Wu H, Tokarski JS, Chen X, Gillooly KM, Kiener PA, Mcintyre KW, Patil-Koota V, Shuster DJ, Turk LA, Yang G, Leftheris K (2003) Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J Med Chem 46:2110–2116
Wurita A, Hasegawa K, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Watanabe K, Suzuki O (2015) Identification and quantitation of 5-fluoro-ADB-PINACA and MAB-CHMINACA in dubious herbal products. Forensic Toxicol 33:213–220
Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ, Salyers AK, Chandran P, Zhu CZ, Zhong C, Ryther K, Gallagher ME, Chin CL, Tovcimak AE, Hradil VP, Fox GB, Dart MJ, Honore P, Meyer MD (2009) Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 328:141–151
Yildirim M, Wals HC, Van VBJ, Lange JHM (2009) 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators. World Patent 2,008,152,086
You H, Gadotti VM, Petrov RR, Zamponi GW, Diaz P (2011) Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. Mol Pain 7:89
Zanda MT, Fattore L (2018) Old and new synthetic cannabinoids: lessons from animal models. Drug Metab Rev 50:54–64
Zuba D, Geppert B, Sekuła K, Żaba C (2013) [1-(Tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone: a new synthetic cannabinoid identified on the drug market. Forensic Toxicol 31:281–291
Zuurman L, Passier PC, De Kam M, Kleijn HJ, Cohen AF, Van Gerven JM (2009) Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. J Psychopharmacol 23:633–644
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Banister, S.D., Connor, M. (2018). The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution. In: Maurer, H., Brandt, S. (eds) New Psychoactive Substances . Handbook of Experimental Pharmacology, vol 252. Springer, Cham. https://doi.org/10.1007/164_2018_144
Download citation
DOI: https://doi.org/10.1007/164_2018_144
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10560-0
Online ISBN: 978-3-030-10561-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)